SFO
BDTX icon

Stokes Family Office’s Black Diamond Therapeutics BDTX Stock Holding History

Stokes Family Office’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,077
Closed -$26.9K – 281
2025
Q4 		$26.9K Buy
+11,077
New +$39.2K ﹤0.01% 309

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Stokes Family Office's BDTX Position: Q1 2026 in Review

Stokes Family Office sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 11,077 shares — an estimated $26.9K sold.

Stokes Family Office first reported a position in BDTX in Q4 2025 and held it in 1 quarter. The position peaked at $26.9K in Q4 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Stokes Family Office reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Stokes Family Office sold 11,077 Black Diamond Therapeutics shares in Q1 2026, an estimated $26.9K.
  • Stokes Family Office first reported a position in Black Diamond Therapeutics in Q4 2025 and held it in 1 quarter.
  • Stokes Family Office's Black Diamond Therapeutics position peaked at $26.9K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Stokes Family Office's 13F filing for Q1 2026, filed 12 May 2026.